Cullinan Therapeutics Announces Appointment of Mary Kay Fenton as Chief Financial Officer
29 avr. 2024 07h00 HE
|
Cullinan Therapeutics, Inc.
CAMBRIDGE, Mass., April 29, 2024 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on modality-agnostic targeted therapies, today announced the...
Cullinan Therapeutics to Present Clinical Data from Phase 1 Study Evaluating Novel Anti-MICA/B Antibody, CLN-619, as Monotherapy and in Combination with a Checkpoint Inhibitor in Patients with Advanced Solid Tumors at ASCO 2024
24 avr. 2024 10h09 HE
|
Cullinan Therapeutics, Inc.
CAMBRIDGE, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on modality-agnostic targeted therapies, today announced that...
Cullinan Therapeutics Announces Strategic Expansion into Autoimmune Diseases
16 avr. 2024 07h00 HE
|
Cullinan Therapeutics, Inc.
CLN-978 clinical development to focus exclusively on autoimmune diseases, pursuing systemic lupus erythematosus as a first indication Clinical observations from CLN-978 B-NHL study show rapid,...
Cullinan Therapeutics Announces Oversubscribed $280 million Private Placement
16 avr. 2024 06h59 HE
|
Cullinan Therapeutics, Inc.
Financing includes new and existing leading life sciences institutional investors Proceeds, along with existing cash and cash equivalents, are expected to extend cash runway into 2028 Cullinan to...
Cullinan Oncology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results
14 mars 2024 07h00 HE
|
Cullinan Oncology, Inc.
Cullinan remains on track to report additional solid tumor dose escalation data for CLN-619 in the second quarter of 2024 and recently received FDA clearance for an IND to evaluate CLN-619 in...
Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for Novel MICA/B Antibody, CLN-619, for Relapsed/Refractory Multiple Myeloma
01 mars 2024 07h00 HE
|
Cullinan Oncology, Inc.
Company will initiate Phase 1 study of CLN-619 for relapsed or refractory multiple myeloma, first MICA/B antibody clinical study in hematologic malignancies Follows ongoing clinical study of...
Cullinan Oncology to Participate in Upcoming Investor Conferences
27 févr. 2024 08h00 HE
|
Cullinan Oncology, Inc.
CAMBRIDGE, Mass., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan Oncology”) a biopharmaceutical company focused on modality-agnostic targeted oncology therapies,...
Cullinan Oncology to Present at the 42nd Annual J.P. Morgan Healthcare Conference
18 déc. 2023 16h53 HE
|
Cullinan Oncology, Inc.
CAMBRIDGE, Mass., Dec. 18, 2023 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan Oncology”) a biopharmaceutical company focused on modality-agnostic targeted oncology...
Cullinan Oncology Announces First Patient Dosed in Phase 1 Trial Evaluating CLN-617, a Novel Fusion Protein Uniquely Harnessing Both IL-2 and IL-12 Cytokines
14 déc. 2023 16h30 HE
|
Cullinan Oncology, Inc.
CAMBRIDGE, Mass., Dec. 14, 2023 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on modality-agnostic, targeted oncology therapies, today announced...
Cullinan Oncology Provides Corporate Update and Reports Third Quarter 2023 Financial Results
08 nov. 2023 07h00 HE
|
Cullinan Oncology, Inc.
Cullinan to provide clinical data updates on three novel targeted oncology programs and complete enrollment in the pivotal Phase 2b portion of the zipalertinib REZILIENT1 study in 2024 Initial...